News &amp; Updates

In the treatment of patients with active psoriatic arthritis (PsA), intravenous secukinumab appears to yield rapid and sustained improvements in clinical measures, with a safety profile consistent with that of the subcutaneous formulation, according to the phase III INVIGORATE-2 study.

Secukinumab infusion shows therapeutic potential in psoriatic arthritis

Remibrutinib offers rapid, sustained symptom relief in patients with CSU

16 Oct 2024 by

Treatment with remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor, led to rapid symptom improvement that lasted for 52 weeks in patients with chronic spontaneous urticaria (CSU), according to the pivotal phase III REMIX-1 and -2 studies presented at EADV 2024.

Remibrutinib offers rapid, sustained symptom relief in patients with CSU

Acute and preventive migraine management with CGRP-targeted therapies

16 Oct 2024 by

At an industry-sponsored meeting during the 10^thCongress of the European Academy of Neurology (EAN 2024), Professor Marja-Liisa Sumelahti of Tampere University in Tampere, Finland, Dr Roni Sharon of the Tel Aviv University in Tel Aviv, Israel, and Dr Margarita Sánchez del Rio of the Clínica Universidad de Navarra in Madrid, Spain, discussed the role of calcitonin gene-related peptide (CGRP)–targeted agents, specifically the oral CGRP receptor antagonist (RA), rimegepant, in early migraine management.

Acute and preventive migraine management with CGRP-targeted therapies

Oxybutynin lowers opioid use after paediatric urologic surgery

A single dose of oxybutynin before urologic surgery helps children with an indwelling urinary drain to reduce their use of opioid after the procedure, a study has shown.

Oxybutynin lowers opioid use after paediatric urologic surgery

Long-term glucocorticoid exposure ups risk of incident CVD

Long-term glucocorticoid levels, particularly cortisone measured in scalp hair, are associated with a higher risk of incident cardiovascular disease (CVD) among younger adults, suggests a study.

Long-term glucocorticoid exposure ups risk of incident CVD

15 Oct 2024

Sexual dysfunction prevalent in women with PAH

Many women with pulmonary arterial hypertension (PAH) with a mild functional impairment suffer from sexual dysfunction, a recent study claims.

Sexual dysfunction prevalent in women with PAH

15 Oct 2024

Music a perioperative aide for lung cancer patients?

Individuals with resectable stage IA to IIIB non-small cell lung cancer (NSCLC) who plan to receive minimally invasive lung surgery may benefit from intensity-based personalized music therapy (IBP-MT) suggests the phase II Music of Lung Health II study.

Music a perioperative aide for lung cancer patients?

15 Oct 2024

Phototherapy for psoriasis at home as good as in the office

Narrowband ultraviolet B (NB-UVB) phototherapy or light therapy performed at home is as good as one done in the doctor’s office in patients with plaque and guttate psoriasis, as shown in the randomized Light Treatment Effectiveness (LITE) trial presented at EADV 2024.

Phototherapy for psoriasis at home as good as in the office

15 Oct 2024

Gilteritinib improves survival in R/R FLT3-mutated AML

Patients with relapsed/refractory (R/R) acute myeloid leukaemia (AML) often have poor prognosis and limited succeeding treatment options. In particular, the presence of FMS-like tyrosine kinase 3 (FLT3) gene mutation adversely affects survival outcomes. At an industry-sponsored symposium, Professor Mark Levis from the Johns Hopkins University in Baltimore, US, discussed the role of the oral selective FLT3 inhibitor, gilteritinib, in patients with R/R FLT3-mutated AML, and shared case studies to demonstrate its applicability in select patients in his clinical practice.

Gilteritinib improves survival in R/R FLT3-mutated AML

Rimegepant shows favourable safety & tolerability in migraine patients with CV risk factors

In migraine patients with cardiovascular (CV) risk factors, including those with moderate to high CV risk, rimegepant for long-term acute treatment of migraine is associated with favourable safety and tolerability, post hoc subgroup analyses of a 52-week multicentre open-label safety study have shown.

Rimegepant shows favourable safety & tolerability in migraine patients with CV risk factors